Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.23.3
Commitments and Contingencies - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Commitments and Contingencies [Line Items]        
Monthly fee included in minimum lease payment       $ 1,127,000
Research and development expense $ 13,787,000 $ 8,216,000 $ 38,019,000 26,900,000
Wuxi Agreement        
Commitments and Contingencies [Line Items]        
Initial Terms of Agreement, Description     Under the August 2023 work orders, WuXi will convert the Company’s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company’s CABA-201 and MuSK-CAART programs (the Dedicated Suite) for an initial term of 18 months with two 18 month extensions at the Company’s sole option on six months' notice prior to the end of the term  
Early termination fee 1,500,000   $ 1,500,000  
Lease expiration month     18 months  
Wuxi Agreement | CABA-201 and MuSK-CAART        
Commitments and Contingencies [Line Items]        
Early termination fee 1,080,000   $ 1,080,000  
Research Service Agreement | Children's Hospital of Philadelphia        
Commitments and Contingencies [Line Items]        
Research and development expense 0 $ 0 0 $ 166,000
Liability related to agreement $ 480,000   $ 480,000